| Literature DB >> 35096180 |
Yasuhiro Igarashi1, Yiwei Ge1, Tao Zhou1, Amit Raj Sharma1, Enjuro Harunari1, Naoya Oku1, Agus Trianto2.
Abstract
HPLC/DAD-based chemical investigation of a coral-associated gliding bacterium of the genus Tenacibaculum yielded three desferrioxamine-class siderophores, designated tenacibactins K (1), L (2), and M (3). Their chemical structures, comprising repeated cadaverine-succinic acid motifs terminated by a hydroxamic acid functionality, were elucidated by NMR and negative MS/MS experiments. Compounds 1-3 were inactive against bacteria and a yeast but displayed cytotoxicity against 3Y1 rat embryonic fibroblasts and P388 murine leukemia cells at GI50 in submicromolar to micromolar ranges. Their iron-chelating activity was comparable to deferoxamine mesylate.Entities:
Keywords: MS/MS analysis; Tenacibaculum; desferrioxamine; marine obligate bacterium; tenacibactin
Year: 2022 PMID: 35096180 PMCID: PMC8767563 DOI: 10.3762/bjoc.18.12
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Figure 1Structures of tenacibactins K–M (1–3).
1H and 13C NMR data for tenacibactin K (1) in DMSO-d6.
| position | δCa, type | δH, mult ( | HMBCb,c |
|
| |||
| 1a | 22.6, CH3 | 0.83, d (6.6) | 1b, 2, 3 |
| 1b | 22.6, CH3 | 0.83, d (6.6) | 1a, 2, 3 |
| 2 | 27.5, CH | 1.48d | 1a, 1b, 3, 4 |
| 3 | 38.56, CH2 | 1.12, m | 1a, 1b, 2, 4, 5 |
| 4 | 26.9, CH2 | 1.22d | |
| 5 | 29.4, CH2 | 1.22d | |
| 6 | 28.88e, CH2 | 1.20 to ≈1.25d | |
| 7 | 28.95e, CH2 | 1.20 to ≈1.25d | |
| 8 | 29.1e, CH2 | 1.20 to ≈1.25d | |
| 9 | 29.2e, CH2 | 1.20 to ≈1.25d | |
| 10 | 28.7, CH2 | 1.33, m | 12f |
| 11 | 28.3, CH2 | 2.49, m | 12f, 13f |
| 12 | 144.5, CH | 5.98, dt (11.4, 7.4)g | 14f |
| 13 | 119.8, CH | 6.30, d (11.4) | 11f, 14f |
| 14 | 166.2, C | ||
| 16 | 46.7, CH2 | 3.48d | 14, 17, 18 |
| 17 | 26.1, CH2 | 1.52d | 16, 18, 19 |
| 18 | 23.6, CH2 | 1.21d | |
| 19 | 28.8, CH2 | 1.37d | 17, 18, 20 |
| 20 | 38.52, CH2 | 3.00d | 18, 19, 22 |
| 21-NH | 7.79, t (4.9) | 20, 22 | |
| 22 | 171.5, C | ||
| 23 | 30.1, CH2 | 2.26, t (7.4) | 22, 24, 25 |
| 24 | 27.7, CH2 | 2.57, t (7.4) | 22, 23, 25 |
| 25 | 172.0, C | ||
| 27 | 47.2, CH2 | 3.45d | 25, 28, 29 |
| 28 | 26.1, CH2 | 1.50d | 27, 29, 30 |
| 29 | 23.6, CH2 | 1.21d | |
| 30 | 28.8, CH2 | 1.37d | 28, 29, 31 |
| 31 | 38.52, CH2 | 2.99d | 29, 30, 33 |
| 32-NH | 7.81, t (5.2) | 31, 33 | |
| 33 | 171.0, C | ||
| 34 | 30.7, CH2 | 2.28, t (7.0) | 33, 35, 36 |
| 35 | 28.0, CH2 | 2.16, t (7.1) | 33, 34, 36 |
| 36 | 168.6, C | ||
| NH or OH | 8.71, brs | ||
| NH or OH | 9.71, brs | ||
| NH or OH | 10.39, brs | ||
aReferenced to a septet peak of DMSO-d6 at 39.5 ppm. bReferenced to a quintet peak from residual DMSO-d6 at 2.50 ppm. cFrom proton to indicated carbons. dOverlapped. eInterchangeable. fObserved in a mixed solvent CDCl3/CD3OD 3:7. gCoupling constants acquired at 50 °C.
Figure 2Key 2D-NMR correlations for 1–3.
Figure 3(a) Partial 1H NMR spectra of 1 at 25 and 50 °C in DMSO-d6; (b) magnified HMBC spectrum of 1 at 25 °C in CDCl3/CD3OD 3:7.
Figure 4MS/MS spectrum of 1 acquired on a quadrupole time-of-flight mass spectrometer in the negative ion mode.
Scheme 1MS/MS fragmentation pathway for compound 1.
1H and 13C NMR data for tenacibactins L (2) and M (3) in DMSO-d6.
|
|
| ||||||
|
|
| ||||||
| position | δCa, type | δH, mult ( | HMBCc | δCa, type | δH, mult ( | HMBCc | |
|
|
| ||||||
| 1a | 22.6, CH3 | 0.83, d (6.6) | 1b, 2, 3 | 22.6, CH3 | 0.83, d (6.6) | 1b, 2, 3 | |
| 1b | 22.6, CH3 | 0.83, d (6.6) | 1a, 2, 3 | 22.6, CH3 | 0.83, d (6.6) | 1a, 2, 3 | |
| 2 | 27.5, CH | 1.48d | 1a, 1b, 3, 4 | 27.5, CH | 1.48d | 1a, 1b, 3, 4 | |
| 3 | 38.52, CH2 | 1.12, m | 1a, 1b, 2, 4, 5 | 38.54, CH2 | 1.12, m | 1a, 1b, 2, 4, 5 | |
| 4 | 26.8, CH2 | 1.22d | 26.8, CH2 | 1.22d | |||
| 5 | 29.3, CH2 | 1.22d | 29.4, CH2 | 1.22d | |||
| 6 | 29.0, CH2 | 1.24d | 28.88e, CH2 | 1.20 to ≈1.25d | |||
| 7 | 28.7, CH2 | 1.23d | 28.92e, CH2 | 1.20 to ≈1.25d | |||
| 8 | 29.1, CH2 | 1.29, m | 7, 9 | 29.07e, CH2 | 1.20 to ≈1.25d | ||
| 9 | 26.6, CH2 | 1.98, dt (6.0, 6.7) | 7, 8, 10, 11 | 29.09e, CH2 | 1.20 to ≈1.25d | ||
| 10 | 130.2, CH | 5.33d | 8, 9, 12 | 29.13e, CH2 | 1.20 to ≈1.25d | ||
| 11 | 128.9, CH | 5.33d | 9, 12, 13 | 29.0, CH | 1.22d | ||
| 12 | 22.3, CH2 | 2.19, dt (6.4, 7.4) | 10, 11, 13, 14 | 24.3, CH2 | 1.45d | 11, 13, 14 | |
| 13 | 32.0, CH2 | 2.36, t (7.7) | 11, 12, 14 | 31.8, CH2 | 2.31, t (7.1) | 11, 12, 14 | |
| 14 | 172.2, C | 172.8, C | |||||
| 16 | 47.2, CH2 | 3.44d | 14, 17, 18 | 47.0, CH2 | 3.44d | 14, 17, 18 | |
| 17 | 26.1, CH2 | 1.48d | 16, 18, 19 | 26.1, CH2 | 1.48d | 16, 18, 19 | |
| 18 | 23.6, CH2 | 1.20d | 23.6, CH2 | 1.20d | |||
| 19 | 28.8, CH2 | 1.37d | 17, 18, 20 | 28.8, CH2 | 1.37d | 17, 18, 20 | |
| 20 | 38.51, CH2 | 2.99d | 18, 19, 22 | 38.52, CH2 | 2.99d | 18, 19, 22 | |
| 21-NH | 7.78, t (5.2) | 20, 22 | 7.80d | 22 | |||
| 22 | 171.5, C | 171.5, C | |||||
| 23 | 30.0, CH2 | 2.26, t (7.1) | 22, 24, 25 | 30.0, CH2 | 2.26d | 22, 24, 25 | |
| 24 | 27.6, CH2 | 2.57, t (7.0) | 22, 23, 25 | 27.7, CH2 | 2.57, t (7.1) | 22, 23, 25 | |
| 25 | 172.0, C | 172.1, C | |||||
| 27 | 47.2, CH2 | 3.44d | 25, 28, 29 | 47.2, CH2 | 3.44d | 25, 28, 29 | |
| 28 | 26.1, CH2 | 1.48d | 27, 29, 30 | 26.1, CH2 | 1.48d | 27, 29, 30 | |
| 29 | 23.6, CH2 | 1.20d | 23.6, CH2 | 1.20d | |||
| 30 | 28.8, CH2 | 1.37d | 28, 29, 31 | 28.8, CH2 | 1.37d | 28, 29, 31 | |
| 31 | 38.51, CH2 | 2.99d | 29, 30, 33 | 38.52, CH2 | 2.99d | 29, 30, 33 | |
| 32-NH | 7.81, t (4.9) | 31, 33 | 7.80d | 33 | |||
| 33 | 171.0, C | 171.0, C | |||||
| 34 | 30.7, CH2 | 2.28, t (7.0) | 33, 35, 36 | 30.7, CH2 | 2.28d | 33, 35, 36 | |
| 35 | 28.0, CH2 | 2.16, t (7.1) | 33, 34, 36 | 28.0, CH2 | 2.16, t (7.2) | 33, 34, 36 | |
| 36 | 168.6, C | 168.6, C | |||||
| NH or OH | 8.71, brs | 8.73, brs | |||||
| NH or OH | 9.69, brs | 9.69, brs | |||||
| NH or OH | 10.39, brs | 10.38, brs | |||||
aReferenced to a septet peak of DMSO-d6 at 39.5 ppm. bReferenced to a quintet peak from residual DMSO-d6 at 2.50 ppm. cFrom proton to indicated carbons. dOverlapped. eInterchangeable.
Cytotoxicity data of compounds 1–3.
| GI50 (μM) | ||||
|
| ||||
| cell line |
|
|
| controla |
|
| ||||
| 3Y1 rat embryonic fibroblasts | 1.4 | 2.8 | 0.60 | 0.058 |
| P388 murine leukemia | 1.1 | 11.6 | 0.38 | 0.061 |
aDoxorubicin hydrochloride.